/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";}

.

Albert Agro, PhD, joined Cynapsus as chief medical officer in August 2010. Dr. Agro also continues to serve as president and CEO of HNZ Strategic Holdings, Inc., a boutique consulting firm that provides innovative clinical development services and counselling to pharmaceutical and biotech companies developing treatments for serious disease.

Prior to this role, Dr. Agro was senior vice president of drug development of TransTech Pharma (2007-2009). From 2003 to 2007, he was a partner at Axon Medical Communications and helped build the clinical research arm of the business (2005-2007), as well as vice president of medical and scientific affairs (2003-2005). Dr. Agro served as director of national medicine, as well as director of immunology, virology and respiratory medicine at Boehringer Ingelheim (2000-2003). He also worked at Bayer Inc., as associate director of cardiopulmonary medicine (1998-2000).

Dr. Agro completed his PhD from the Department of Medicine at McMaster University in 1995. After a postdoctoral fellowship at the University of Florence in Italy, Dr. Agro accepted an academic position as assistant professor, Department of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario, which he still maintains today.